{"entity":{"id":"nct06358573","kind":"trial","name":"Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK","aka":["INVINCIBLE-4"],"tldr":"A phase 2 trial of INT230-6 in triple-negative breast cancer, run by Swiss Cancer Institute, now recruiting.","summary":"Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK is a phase 2, randomised interventional study registered as NCT06358573 by Swiss Cancer Institute, with a registry enrolment figure of 61 participants, started 2024-10-24 and due to reach its primary completion in 2028-10. Interventions recorded: INT230-6; neoadjuvant immuno-chemotherapy. Conditions listed: Triple-negative Breast Cancer; TNBC - Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"* Newly histologically diagnosed, previously untreated locally advanced non-metastatic TNBC as defined by the most recent American Society of Clinical Oncology (ASCO) / College of American Pathologist (CAP) guidelines\". Sites: France, Switzerland. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06358573","url":"https://clinicaltrials.gov/study/NCT06358573"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early","tnbc-metastatic"],"sections":[],"technologies":[],"targets":[],"drugs":["int230-6"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06358573","phase":"2","setting":"Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early Triple-negative Breast Cancer (TNBC). An Open-label Randomized Two-cohort Phase 2 Clinical Trial. INVINCIBLE-4-SAKK","sponsor":"Swiss Cancer Institute","participation":[{"nct":"NCT06358573","source":"https://clinicaltrials.gov/study/NCT06358573","fetchedAt":"2026-10-07T16:54:34.595Z","studySha256":"73fd31702a660cf11f6bf8e528a1ba2925f4ff36ab8c16d72dfd3b0d62eae50f","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-17","leadSponsor":"Swiss Cancer Institute","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":61,"enrolmentType":"ESTIMATED","siteCount":10,"recruitingSiteCount":8,"countries":["France","Switzerland"]}],"started":"2024-10-24","startedType":"actual","enrolled":61,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06358573/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"drug":[{"id":"int230-6","kind":"drug","name":"INT230-6","route":"/drugs/int230-6/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}